Metformin effects on the heart and the cardiovascular system: A review of experimental and clinical data - PubMed
Review
. 2017 Aug;27(8):657-669.
doi: 10.1016/j.numecd.2017.04.009. Epub 2017 May 10.
Affiliations
- PMID: 28709719
- DOI: 10.1016/j.numecd.2017.04.009
Review
Metformin effects on the heart and the cardiovascular system: A review of experimental and clinical data
L Nesti et al. Nutr Metab Cardiovasc Dis. 2017 Aug.
Abstract
Background: Metformin, the eldest and most widely used glucose lowering drug, is likely to be effective also on cardiac and vascular disease prevention. Nonetheless, uncertainty still exists with regard to its effects on the cardiovascular system as a whole and specifically on the myocardium, both at the organ and cellular levels.
Methods: We reviewed the available data on the cardiac and vascular effects of metformin, encompassing both in vitro, either tissue or isolated organ, and in vivo studies in experimental animals and humans, as well as the evidence generated by major clinical trials.
Results: At the cellular level metformin's produces both AMP-activated kinase (AMPK) dependent and independent effects. At the systemic level, possibly also through other pathways, this drug improves endothelial function, protects from oxidative stress and inflammation, and from the negative effects of angiotensin II. On the myocardium it attenuates ischemia-reperfusion injury and prevents adverse remodeling induced by humoral and hemodynamic factors. The effects on myocardial cell metabolism and contractile function being not evident at rest or in more advanced stages of cardiac dysfunction, could be relevant during transient ischemia, during an acute increase in workload and in the early stages of diabetic/hypertensive cardiomyopathy as confirmed by few small clinical trials and some observational studies. The overall evidence emerging from both clinical trials and real world registry is in favor of a protective effect of metformin with respect to both coronary events and progression to heart failure.
Conclusions: Given this potential, its efficacy and its safety (and also its low cost) metformin remains the central pillar of the therapy of diabetes.
Keywords: Cardiovascular; Heart; Metformin.
Copyright © 2017 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Paneni F, Costantino S, Cosentino F. Paneni F, et al. G Ital Cardiol (Rome). 2015 Apr;16(4):225-31. doi: 10.1714/1848.20186. G Ital Cardiol (Rome). 2015. PMID: 25959758 Review. Italian.
-
Endothelial function and dysfunction: Impact of metformin.
Nafisa A, Gray SG, Cao Y, Wang T, Xu S, Wattoo FH, Barras M, Cohen N, Kamato D, Little PJ. Nafisa A, et al. Pharmacol Ther. 2018 Dec;192:150-162. doi: 10.1016/j.pharmthera.2018.07.007. Epub 2018 Jul 27. Pharmacol Ther. 2018. PMID: 30056057 Review.
-
Cheang WS, Tian XY, Wong WT, Lau CW, Lee SS, Chen ZY, Yao X, Wang N, Huang Y. Cheang WS, et al. Arterioscler Thromb Vasc Biol. 2014 Apr;34(4):830-6. doi: 10.1161/ATVBAHA.113.301938. Epub 2014 Jan 30. Arterioscler Thromb Vasc Biol. 2014. PMID: 24482374
-
Metformin: from mechanisms of action to therapies.
Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Foretz M, et al. Cell Metab. 2014 Dec 2;20(6):953-66. doi: 10.1016/j.cmet.2014.09.018. Epub 2014 Oct 30. Cell Metab. 2014. PMID: 25456737 Review.
-
Venu VKP, Saifeddine M, Mihara K, Faiza M, Gorobets E, Flewelling AJ, Derksen DJ, Hirota SA, Marei I, Al-Majid D, Motahhary M, Ding H, Triggle CR, Hollenberg MD. Venu VKP, et al. Mol Pharmacol. 2021 Nov;100(5):428-455. doi: 10.1124/molpharm.120.000148. Epub 2021 Aug 27. Mol Pharmacol. 2021. PMID: 34452975
Cited by
-
Tseng CH. Tseng CH. J Am Heart Assoc. 2019 Nov 5;8(21):e011640. doi: 10.1161/JAHA.118.011640. Epub 2019 Oct 21. J Am Heart Assoc. 2019. PMID: 31630591 Free PMC article.
-
Yu XJ, Zhao YN, Hou YK, Li HB, Xia WJ, Gao HL, Liu KL, Su Q, Yang HY, Liang B, Chen WS, Cui W, Li Y, Zhu GQ, Yang ZM, Kang YM. Yu XJ, et al. Neurosci Bull. 2019 Feb;35(1):57-66. doi: 10.1007/s12264-018-0308-5. Epub 2018 Nov 14. Neurosci Bull. 2019. PMID: 30426340 Free PMC article.
-
Physical Exercise and Its Protective Effects on Diabetic Cardiomyopathy: What Is the Evidence?
Zheng J, Cheng J, Zheng S, Zhang L, Guo X, Zhang J, Xiao X. Zheng J, et al. Front Endocrinol (Lausanne). 2018 Dec 3;9:729. doi: 10.3389/fendo.2018.00729. eCollection 2018. Front Endocrinol (Lausanne). 2018. PMID: 30559720 Free PMC article. Review.
-
Samuel SM, Varghese E, Kubatka P, Triggle CR, Büsselberg D. Samuel SM, et al. Biomolecules. 2019 Dec 9;9(12):846. doi: 10.3390/biom9120846. Biomolecules. 2019. PMID: 31835318 Free PMC article. Review.
-
Park JM, Shin JH, Yang SW, Lee JY, Lee CL, Lim JS, Song KH, Kim GH, Na YG. Park JM, et al. Int Neurourol J. 2021 Dec;25(4):285-295. doi: 10.5213/inj.2142206.103. Epub 2021 Sep 3. Int Neurourol J. 2021. PMID: 34530523 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical